Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
MedPage Today on MSN
First complement inhibitor wins full approval in IgA nephropathy
Iptacopan significantly slowed kidney decline in a phase III trial ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
The treatment landscape for C3G has historically depended on the off-label use of multiple prescription therapies, ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results